Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Chao Jiang , Zhao Zixu Added: 6 months ago
AHA Scientific Sessions 2025 – Dr Chao Jiang and Dr Zhao Zixu (Beijing Anzhen Hospital, CN) discuss the findings from the DARE-AF (NCT06433479) randomized clinical trial, investigating whether dapagliflozin reduces atrial fibrillation burden following catheter ablation in patients without diabetes or heart failure.This single-center, open-label trial enrolled 200 patients with persistent atrial… View more
Added: 10 months ago Source:  Radcliffe Cardiology
The long-term utility of beta-blockers following an uncomplicated myocardial infarction (MI) remains a subject of clinical debate. New secondary results from the AβYSS trial (Assessment of β-blocker interruption one Year after an uncomplicated myocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization) reveal that interrupting this therapy leads to sustained… View more
Author(s): Lucas Boersma Added: 1 month ago
HRS Congress 2026 – Prof Lucas Boersma (St. Antonius Hospital, Nieuwegein, NL) joins us to discuss real-world periprocedural outcomes from the Enlighten post-market registry study evaluating the extravascular implantable cardioverter-defibrillator (EV-ICD) system, and how these compare to findings from pre-market clinical trials.The Enlighten study is an ongoing, global, prospective post-market… View more
Author(s): Emma Sandgren , Dominik Linz , Added: 2 months ago
Prof Dominik Linz (Maastricht University Medical Centre, Maastricht, NL) moderates a discussion with Dr Emma Sandgren (Karolinska Institutet Danderyd Hospital, Stockholm, SE) and Dr Martin Manninger-Wünscher (Medical University of Graz, Graz, AU) on the clinical implementation and future potential of photoplethysmography (PPG) in atrial fibrillation management.The panel explores PPG's role as a… View more
Author(s): Devi Nair , Vivek Reddy Added: 2 months ago
ACC.26 - At ACC.26 in New Orleans, Dr Devi Nair (Arkansas, US) and Dr Vivek Reddy (New York, US) dissect the late-breaking CHAMPION‑AF trial, a large randomized comparison of first-line left atrial appendage closure with WATCHMAN FLX versus continued NOAC therapy in patients with non-valvular AF who can tolerate anticoagulation. They review the trial design, post‑implant antithrombotic and… View more